Activation of STING-dependent innate immune signaling by S-phase-specific DNA damage in breast cancer by Parkes, EE, Walker, SM, Taggart, LE, McCabe, N, Knight, LA, Wilkinson, R, McCloskey, KD, Buckley, NE, Savage, KI, Salto-Tellez, M, McQuaid, S, Harte, MT, Mullan, PB, Harkin, DP, Kennedy, RD

Automated tumour recognition and digital pathology scoring unravels new role for PD-L1 in predicting good outcome in ER-/HER2+ breast cancer by Humphries, MP, Hynes, S, Bingham, V, Cougot, D, James, J, Patel-Socha, F, Parkes, EE, Blayney, JK, O’Rorke, MA, Irwin, GW, McArt, DG, Kennedy, RD, Mullan, PB, McQuaid, S, Salto-Tellez, M, Buckley, NE

Translational analysis of esophageal adenocarcinoma (EAC) patients treated with oxaliplatin and capecitabine (Xelox) +/- the dual ErbB inhibitor AZD8931 in the DEBIOC study by Lavery, A, Stevenson, L, McManus, D, Logan, GE, Walker, SM, Jellema, GL, Van Schaeybroeck, S, Virdee, PS, Middleton, MR, Elhussein, L, Turbitt, J, Colinson, D, Miedzybrodzka, Z, Petty, RD, Harkin, PD, Kennedy, RD, Eatock, MM, Thomas, AL, Turkington, RC

Validation of the DNA damage immune response signature in patients with triple-negative breast cancer from the SWOG 9313c trial by Sharma, P, Barlow, WE, Godwin, AK, Parkes, EE, Knight, LA, Walker, SM, Kennedy, RD, Harkin, DP, Logan, GE, Steele, CJ, Lambe, SM, Badve, S, Gökmen-Polar, Y, Pathak, HB, Isakova, K, Linden, HM, Porter, P, Pusztai, L, Thompson, AM, Tripathy, D, Hortobagyi, GN, Hayes, DF

Molecular subgroup of primary prostate cancer presenting with metastatic biology. by Walker, SM, Knight, LA, McCavigan, AM, Logan, GE, Berge, V, Sherif, A, Pandha, H, Warren, AY, Davidson, C, Uprichard, A, Blayney, JK, Price, B, Jellema, GL, Steele, CJ, Svindland, A, McDade, SS, Eden, CG, Foster, C, Mills, IG, Neal, DE, Mason, MD, Kay, EW, Waugh, DJ, Harkin, DP, Watson, RW, Clarke, NW, Kennedy, RD

In-depth clinical and biological exploration of DNA damage immune response as a biomarker for oxaliplatin use in colorectal cancer by Malla, SB, Fisher, DJ, Domingo, E, Blake, A, Hassanieh, S, Redmond, KL, Richman, SD, Youdell, M, Walker, SM, Logan, GE, Chatzipli, A, Amirkhah, R, Humphries, MP, Craig, SG, McDermott, U, Seymour, MT, Morton, DG, Quirke, P, West, NP, Salto-Tellez, M, Kennedy, RD, Johnston, PG, Tomlinson, I, Koelzer, VH, Campo, L, Kaplan, RS, Longley, DB, Lawler, M, Maughan, TS, Brown, LC, Dunne, PD

Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma by Turkington, RC, Knight, LA, Blayney, JK, Secrier, M, Douglas, R, Parkes, EE, Sutton, EK, Stevenson, L, McManus, D, Halliday, S, McCavigan, AM, Logan, GE, Walker, SM, Steele, CJ, Perner, J, Bornschein, J, MacRae, S, Miremadi, A, McCarron, E, McQuaid, S, Arthur, K, James, JA, Eatock, MM, O'Neill, R, Noble, F, Underwood, TJ, Harkin, DP, Salto-Tellez, M, Fitzgerald, RC, Kennedy, RD, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group